Second-quarter catalysts for the smaller players

After delving into the key clinical events due for big pharma and biotech companies, Evaluate Vantage here looks at smaller players − those with a market cap of under $1bn.

Orphazyme's recent setback with arimoclomol in a muscle-wasting disease puts a damper on upcoming data in amyotrophic lateral sclerosis (ALS). Meanwhile, Gemini's new approach to geographic atrophy will yield data, and Immutep hopes to rebound with results on its Lag3 project eftilagimod alpha.